Meta-analysis of prevalence: the psychological sequelae among COVID-19 survivors.

IF 2.9 4区医学 Q2 PSYCHIATRY

International Journal of Psychiatry in Clinical Practice Pub Date : 2022-09-01 Epub Date: 2021-10-28 DOI:10.1080/13651501.2021.1993924

Bann Khraisat, Ahmad Toubasi, Lujain AlZoubi, Thuraya Al-Sayegh, Ahmad Mansour

{"title":"Meta-analysis of prevalence: the psychological sequelae among COVID-19 survivors.","authors":"Bann Khraisat, Ahmad Toubasi, Lujain AlZoubi, Thuraya Al-Sayegh, Ahmad Mansour","doi":"10.1080/13651501.2021.1993924","DOIUrl":null,"url":null,"abstract":"Objective: This meta-analysis aims to estimate the pooled prevalence of mental disorders among COVID-19 survivors.Methods: The databases Pubmed, Google Scholar, ScienceDirect, and medRxiv have been searched up to 1 August 2021 using COVID-19, survivors, mental disorders, and their related MeSH terms. The included studies were either cross-sectional, cohort, or case-control in design. Those studies included COVID-19 survivors after 14 or more days from their COVID-19 recovery and used validated questionnaires to assess their mental health outcomes. The random-effects model was used to pool the data from the incorporated studies. The heterogeneity was assessed using Cochran's Q heterogeneity test and I2 statistic.Results: Twenty-seven studies were included in the data synthesis with a total sample size of 9605 COVID-19 survivors. The prevalence rates for Post-Traumatic Stress Disorder (PTSD), anxiety, psychological distress, depression, and sleeping disorders were 20% (95% CI = 16-24%), 22% (95% CI = 18-27%), 36% (95% CI = 22-51%), 21% (95% CI = 16-28%), and 35% (95% CI = 29-41%), respectively.Conclusions: Although we found high heterogeneity across the included studies, our meta-analysis provides evidence that there are psychological sequelae in COVID-19 survivors that require medical assiduity as well as further research on the matter.KEY POINTSIncreased prevalence of psychological sequelae among COVID-19 survivors.The prevalence of PTSD was 20% (95% CI = 16-24%) and of anxiety was 22% (95% CI = 18-27%) among COVID-19 survivors.The prevalence of psychological distress was 36% (95% CI = 22-51%), of depression was 21% (95% CI = 16-28%), and of sleep disorders was 35% (95% CI = 29-41%) among COVID-19 survivors.Future researches are recommended to search for effective and safe methods to mitigate the psychological sequelae in COVID-19 patients.","PeriodicalId":14351,"journal":{"name":"International Journal of Psychiatry in Clinical Practice","volume":"26 3","pages":"234-243"},"PeriodicalIF":2.9000,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"28","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Psychiatry in Clinical Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13651501.2021.1993924","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/10/28 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PSYCHIATRY","Score":null,"Total":0}

引用次数: 28

Abstract

Objective: This meta-analysis aims to estimate the pooled prevalence of mental disorders among COVID-19 survivors.

Methods: The databases Pubmed, Google Scholar, ScienceDirect, and medRxiv have been searched up to 1 August 2021 using COVID-19, survivors, mental disorders, and their related MeSH terms. The included studies were either cross-sectional, cohort, or case-control in design. Those studies included COVID-19 survivors after 14 or more days from their COVID-19 recovery and used validated questionnaires to assess their mental health outcomes. The random-effects model was used to pool the data from the incorporated studies. The heterogeneity was assessed using Cochran's Q heterogeneity test and I² statistic.

Results: Twenty-seven studies were included in the data synthesis with a total sample size of 9605 COVID-19 survivors. The prevalence rates for Post-Traumatic Stress Disorder (PTSD), anxiety, psychological distress, depression, and sleeping disorders were 20% (95% CI = 16-24%), 22% (95% CI = 18-27%), 36% (95% CI = 22-51%), 21% (95% CI = 16-28%), and 35% (95% CI = 29-41%), respectively.

Conclusions: Although we found high heterogeneity across the included studies, our meta-analysis provides evidence that there are psychological sequelae in COVID-19 survivors that require medical assiduity as well as further research on the matter.KEY POINTSIncreased prevalence of psychological sequelae among COVID-19 survivors.The prevalence of PTSD was 20% (95% CI = 16-24%) and of anxiety was 22% (95% CI = 18-27%) among COVID-19 survivors.The prevalence of psychological distress was 36% (95% CI = 22-51%), of depression was 21% (95% CI = 16-28%), and of sleep disorders was 35% (95% CI = 29-41%) among COVID-19 survivors.Future researches are recommended to search for effective and safe methods to mitigate the psychological sequelae in COVID-19 patients.

查看原文本刊更多论文

流行病学荟萃分析:COVID-19幸存者的心理后遗症

目的:本荟萃分析旨在估计COVID-19幸存者中精神障碍的总患病率。方法:使用COVID-19、幸存者、精神障碍及其相关MeSH术语，检索截至2021年8月1日的Pubmed、Google Scholar、ScienceDirect和medRxiv数据库。纳入的研究在设计上为横断面、队列或病例对照。这些研究包括COVID-19康复后14天或更长时间的COVID-19幸存者，并使用有效的问卷来评估他们的心理健康结果。随机效应模型用于汇总合并研究的数据。采用Cochran’s Q异质性检验和I2统计量评估异质性。结果:数据综合纳入27项研究，总样本量为9605例COVID-19幸存者。创伤后应激障碍(PTSD)、焦虑、心理困扰、抑郁和睡眠障碍的患病率分别为20% (95% CI = 16-24%)、22% (95% CI = 18-27%)、36% (95% CI = 22-51%)、21% (95% CI = 16-28%)和35% (95% CI = 29-41%)。结论:尽管我们发现纳入的研究存在高度异质性，但我们的荟萃分析提供的证据表明，COVID-19幸存者存在心理后遗症，需要医疗援助以及对此问题的进一步研究。COVID-19幸存者中心理后遗症的患病率增加。在COVID-19幸存者中，PTSD患病率为20% (95% CI = 16-24%)，焦虑患病率为22% (95% CI = 18-27%)。在COVID-19幸存者中，心理困扰的患病率为36% (95% CI = 22-51%)，抑郁症的患病率为21% (95% CI = 16-28%)，睡眠障碍的患病率为35% (95% CI = 29-41%)。建议未来的研究寻找有效和安全的方法来减轻COVID-19患者的心理后遗症。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Psychiatry in Clinical Practice 医学-精神病学

CiteScore

6.00

自引率

3.30%

发文量

审稿时长

>12 weeks

期刊介绍： International Journal of Psychiatry in Clinical Practice provides an international forum for communication among health professionals with clinical, academic and research interests in psychiatry. The journal gives particular emphasis to papers that integrate the findings of academic research into realities of clinical practice. Focus on the practical aspects of managing and treating patients. Essential reading for the busy psychiatrist, trainee and interested physician. Includes original research papers, comprehensive review articles and short communications. Key words: Psychiatry, Neuropsychopharmacology, Mental health, Neuropsychiatry, Clinical Neurophysiology, Psychophysiology, Psychotherapy, Addiction, Schizophrenia, Depression, Bipolar Disorders and Anxiety.